Microcap Ledger Cerenome, Inc. $CNSY
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 7,589,625 [10-Q 2026-08-14]
What the company doesAI summary of filing
Plus Therapeutics is a clinical-stage healthcare company developing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. The company's lead radiopharmaceutical candidate, rhenium-186 obisbemeda, is in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with funding from the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. Through its subsidiary CNSide Diagnostics, the company commercializes laboratory-developed tests for detecting tumor cells in cerebrospinal fluid and has recently secured insurance coverage agreements with major payors. The company is pre-revenue on its radiopharmaceutical candidates but has begun generating revenue from its CNSide diagnostic test. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.44M | −$15.95M | −$13.37M | $2.37M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $5.21M | −$22.39M | −$20.77M | $4.26M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $5.82M | −$12.98M | −$10.55M | $76.0K | [10-K 2026-03-12] |
- Quarterly cash burn
- −$6.68M
- Cash runway Estimate
- ~1.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 5,896,333 | [10-Q 2024-11-14] |
| 2025-03-21 | 16,999,626 | [10-K 2025-03-31] |
| 2025-05-27 | 32,717,054 | [10-Q 2025-05-30] |
| 2025-08-08 | 99,264,526 | [10-Q 2025-08-14] |
| 2025-10-29 | 137,429,055 | [10-Q 2025-10-30] |
| 2026-03-10 | 171,550,698 | [10-K 2026-03-12] |
| 2026-05-13 | 6,883,106 | [10-Q 2026-05-15] |
| 2026-08-05 | 7,589,625 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-06-02; declared effective 2026-06-05 [S-3 2026-06-02]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-06] |
| 2025-05-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-23] |
| 2025-05-19 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-19] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Van Es-Johansson An | exercise | 921 | — | [4 2026-10-01] |
| 2026-10-01 | Hawkins Richard J | exercise | 921 | — | [4 2026-10-01] |
| 2026-10-01 | Clowes Howard | exercise | 921 | — | [4 2026-10-01] |
| 2026-10-01 | Sims Andrew John Hugh Macintyre | exercise | 1,533 | — | [4 2026-10-01] |
| 2026-10-01 | Sims Andrew John Hugh Macintyre | exercise | 1,165 | — | [4 2026-10-01] |
| 2026-10-01 | Sims Andrew John Hugh Macintyre | exercise | 287 | — | [4 2026-10-01] |
| 2026-10-01 | Andrews Ronald Asbury | exercise | 921 | — | [4 2026-10-01] |
| 2026-10-01 | Hedrick Marc H | exercise | 6,387 | — | [4 2026-10-01] |
| 2026-10-01 | Hedrick Marc H | exercise | 8,066 | — | [4 2026-10-01] |
| 2026-10-01 | Hedrick Marc H | exercise | 1,986 | — | [4 2026-10-01] |
| 2026-10-01 | Guse Kyle | exercise | 921 | — | [4 2026-10-01] |
| 2026-07-01 | Andrews Ronald Asbury | exercise | 922 | — | [4 2026-07-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | 8-K | Other events |
| 2026-09-10 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-04 | 8-K | Charter, bylaws or fiscal year change |
| 2026-06-05 | 8-K | Material agreement entered |
| 2026-06-05 | S-3/A | Registration statement |
| 2026-06-02 | S-3 | Registration statement |
| 2026-05-15 | 8-K | Shareholder vote results |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-15 | 8-K | Results of operations |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $CNSY
Email me when Cerenome, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.